E Fund Management Hong Kong Co. Ltd. Purchases 60 Shares of Axon Enterprise, Inc $AXON

E Fund Management Hong Kong Co. Ltd. grew its position in Axon Enterprise, Inc (NASDAQ:AXON) by 272.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 82 shares of the biotechnology company’s stock after purchasing an additional 60 shares during the quarter. E Fund Management Hong Kong Co. Ltd.’s holdings in Axon Enterprise were worth $68,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. TCI Wealth Advisors Inc. bought a new position in Axon Enterprise during the second quarter worth $214,000. Kentucky Retirement Systems Insurance Trust Fund bought a new position in Axon Enterprise during the first quarter worth $1,110,000. Quotient Wealth Partners LLC bought a new position in Axon Enterprise during the first quarter worth $438,000. CX Institutional bought a new position in Axon Enterprise during the first quarter worth $115,000. Finally, GAMMA Investing LLC boosted its stake in Axon Enterprise by 11.8% during the first quarter. GAMMA Investing LLC now owns 1,454 shares of the biotechnology company’s stock worth $765,000 after acquiring an additional 154 shares in the last quarter. 79.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CFO Brittany Bagley sold 5,000 shares of the stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $713.88, for a total value of $3,569,400.00. Following the completion of the sale, the chief financial officer owned 93,592 shares in the company, valued at $66,813,456.96. This represents a 5.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Jennifer H. Mak sold 77 shares of the stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $760.00, for a total transaction of $58,520.00. Following the completion of the sale, the chief accounting officer owned 15,003 shares of the company’s stock, valued at approximately $11,402,280. This represents a 0.51% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 59,932 shares of company stock valued at $45,115,616 over the last 90 days. 4.40% of the stock is currently owned by company insiders.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $727.41 on Thursday. The firm has a 50-day moving average of $756.79 and a 200-day moving average of $710.65. The company has a market cap of $57.10 billion, a P/E ratio of 179.61, a P/E/G ratio of 27.75 and a beta of 1.41. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. Axon Enterprise, Inc has a one year low of $422.21 and a one year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating the consensus estimate of $1.54 by $0.58. The company had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm’s revenue for the quarter was up 32.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.20 earnings per share. Axon Enterprise has set its FY 2025 guidance at EPS. Equities research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AXON. Wolfe Research began coverage on shares of Axon Enterprise in a research note on Monday, July 7th. They set an “outperform” rating on the stock. Northland Securities set a $800.00 target price on shares of Axon Enterprise in a research note on Tuesday, August 5th. Bank of America upped their price objective on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Morgan Stanley set a $885.00 price objective on shares of Axon Enterprise and gave the stock an “overweight” rating in a report on Friday, July 11th. Finally, Needham & Company LLC restated a “buy” rating and set a $870.00 price objective on shares of Axon Enterprise in a report on Wednesday, September 24th. Fourteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $841.64.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.